Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R8 | Q9NYW2 | 12/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8030958 | 0.88 | ELANE (0.46) | TAS2R8ELANEARIGF1R | |
| SCHEMBL1773465 | 0.87 | IGF1R (0.51) | TAS2R8ARIGF1R | |
| SCHEMBL12603120 | 0.83 | IGF1R (0.44) | TAS2R8ELANEARIGF1R | |
| SCHEMBL8032947 | 0.83 | AR (0.44) | TAS2R8ELANEARIGF1RMCHR1 | |
| SCHEMBL8020844 | 0.82 | TAS2R8 (0.46) | TAS2R8ELANEARIGF1RCYP3A4 | |
| SCHEMBL8034741 | 0.81 | IGF1R (0.43) | TAS2R8ELANEARIGF1RMCHR1 | |
| SCHEMBL8017974 | 0.81 | TAS2R8 (0.45) | TAS2R8ELANEARIGF1R | |
| SCHEMBL1774119 | 0.81 | TAS2R8 (0.43) | TAS2R8ARIGF1RMCHR1 | |
| SCHEMBL1773797 | 0.81 | MGLL (0.45) | TAS2R8ELANEARIGF1RMCHR1 | |
| SCHEMBL8029473 | 0.81 | TAS2R8 (0.46) | TAS2R8AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112097-A1 | Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | disclosed |
| US-20110112097-A1 | Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | disclosed |
| WO-2009097997-A1 | SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112097-A1 | Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | GIPR, PGC, DDC | TAS2R8 238/4885ELANE 1124/4885AR 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.